434 Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84) - Elizabeth Evans; Crystal Mallow; Ernest Smith; Maurice Zauderer; Marya Chaney; Terrence Fisher; Amber Foster; John Leonard (Journal for ImmunoTherapy of Cancer, 2021)